J u m p t o c o n t e n t
M a i n m e n u
M a i n m e n u
N a v i g a t i o n
● M a i n p a g e ● C o n t e n t s ● C u r r e n t e v e n t s ● R a n d o m a r t i c l e ● A b o u t W i k i p e d i a ● C o n t a c t u s ● D o n a t e
C o n t r i b u t e
● H e l p ● L e a r n t o e d i t ● C o m m u n i t y p o r t a l ● R e c e n t c h a n g e s ● U p l o a d f i l e
S e a r c h
Search
A p p e a r a n c e
● C r e a t e a c c o u n t ● L o g i n
P e r s o n a l t o o l s
● C r e a t e a c c o u n t ● L o g i n
P a g e s f o r l o g g e d o u t e d i t o r s l e a r n m o r e ● C o n t r i b u t i o n s ● T a l k
( T o p )
1 R e f e r e n c e s
2 E x t e r n a l l i n k s
T o g g l e t h e t a b l e o f c o n t e n t s
L o k i v e t m a b
3 l a n g u a g e s
● D e u t s c h ● ف ا ر س ی ● I t a l i a n o
E d i t l i n k s
● A r t i c l e ● T a l k
E n g l i s h
● R e a d ● E d i t ● V i e w h i s t o r y
T o o l s
T o o l s
A c t i o n s
● R e a d ● E d i t ● V i e w h i s t o r y
G e n e r a l
● W h a t l i n k s h e r e ● R e l a t e d c h a n g e s ● U p l o a d f i l e ● S p e c i a l p a g e s ● P e r m a n e n t l i n k ● P a g e i n f o r m a t i o n ● C i t e t h i s p a g e ● G e t s h o r t e n e d U R L ● D o w n l o a d Q R c o d e ● W i k i d a t a i t e m
P r i n t / e x p o r t
● D o w n l o a d a s P D F ● P r i n t a b l e v e r s i o n
A p p e a r a n c e
F r o m W i k i p e d i a , t h e f r e e e n c y c l o p e d i a
Whole antibody
interleukin 31 (IL-31)
Cytopoint
subcutaneous injection
Lokivetmab , trade name Cytopoint , is a monoclonal antibody used to treat atopic dermatitis in dogs.[1] interleukin 31 (IL-31),[2] cytokine involved in causing itchiness (pruritus).[2] [3]
The United States Department of Agriculture (USDA) approved lokivetmab (manufactured by Zoetis and sold under the trade name Cytopoint) in December 2016,[3] European Medicines Agency in 2017.[4] [4]
References [ edit ]
^ a b McKay L (13 July 2017). "Making a difference for dogs with atopic dermatitis: When to use Apoquel and when to use Cytopoint" . dvm360.com . Retrieved 2018-07-07 .
^ a b "First antibody therapy in veterinary medicine launched for dogs in the UK". The Veterinary Record . 181 (1 ): 6–7. July 2017. doi :10.1136/vr.j3147 . PMID 28667135 . S2CID 20166012 .
External links [ edit ]
"Lokivetmab" . Drug Information Portal . U.S. National Library of Medicine.
Cyproterone acetate
Flutamide
Spironolactone
Antifungals
Antihistamines
Calcineurin inhibitors
Isotretinoin
Keratolytics
Lithium salts
Topical corticosteroids hydrocortisone )
Mequinol
Monobenzone
Melanotan II
Gamolenic acid
Pimecrolimus
Tacrolimus
Alitretinoin
Topical corticosteroids hydrocortisone )
Dutasteride
Finasteride
Saw palmetto extract
Antiandrogens
Potassium channel openers
Others
Finasteride
Antiandrogens
Eflornithine
Aminobenzoate potassium
Androgens (e.g., testosterone )
Brimonidine
Caffeine
Calcium gluconate
Collagen
Crisaborole
Cromoglicic acid
Deoxycholic acid
Diclofenac
Dupilumab
Estrogens (e.g., estradiol )
Glycopyrronium tosylate
Hyaluronic acid
Hydrogen peroxide
Ivermectin
Magnesium sulfate
Metandienone
Oxymetazoline
Pregnenolone acetate
Progestogens (e.g., progesterone )
Povidone-iodine
Tiratricol
Tralokinumab
Atorolimumab
Avelumab
Avdoralimab
Belimumab
Bleselumab
Brodalumab
Camidanlumab tesirine
Carlumab
Cemiplimab
Dupilumab
Eldelumab
Emapalumab
Fresolimumab
Golimumab
Ianalumab †
Lanadelumab
Lenzilumab
Lerdelimumab
Lirentelimab
Lirilumab
Mavrilimumab
Metelimumab
Morolimumab
Namilumab
Oleclumab
Oxelumab §
Pamrevlumab
Placulumab
Relatlimab †
Sarilumab
Sifalimumab
Tabalumab
Tezepelumab
Ulocuplumab
Varlilumab
Elsilimomab
Faralimomab
Gavilimomab
Inolimomab
Maslimomab
Nerelimomab
Odulimomab
Telimomab aritox
Vepalimomab
Zolimomab aritox
Basiliximab
Clenoliximab
Galiximab
Gomiliximab
Infliximab
Keliximab
Lumiliximab
Priliximab
Teneliximab
Vapaliximab
Aselizumab
Atezolizumab
Benralizumab
Camrelizumab †
Cedelizumab
Certolizumab pegol
Crizanlizumab
Daclizumab
Eculizumab
Efalizumab ‡
Epratuzumab
Erlizumab
Etrolizumab †
Fontolizumab
Frexalimab †
Inebilizumab
Itolizumab
Lampalizumab †
Letolizumab
Ligelizumab †
Lulizumab pegol
Mepolizumab
Mogamulizumab
Natalizumab
Ocrelizumab
Omalizumab
Ozoralizumab
Pascolizumab
Pateclizumab
Pembrolizumab
Pexelizumab
Pidilizumab
Plozalizumab
PRO 140 †
Quilizumab
Ravulizumab
Reslizumab
Retifanlimab
Rontalizumab
Rovelizumab
Ruplizumab
Samalizumab
Satralizumab
Siplizumab
Spartalizumab †
Talizumab
Teclistamab
Teplizumab
Tislelizumab
Tocilizumab
Toralizumab
Tregalizumab
Vatelizumab
Vedolizumab
Visilizumab
Vobarilizumab
TGN1412 §
Immune activation : Dostarlimab Other: Ibalizumab
Rozanolixizumab
Sutimlimab
Canakinumab
Fezakinumab
Fletikumab
Guselkumab
Secukinumab
Sirukumab
Tralokinumab
Ustekinumab
Bimekizumab
Clazakizumab
Gevokizumab
Ixekizumab
Mirikizumab †
Lebrikizumab
Olokizumab †
Perakizumab
Risankizumab
Spesolimab
Tildrakizumab
Sulesomab
t
e
R e t r i e v e d f r o m " https://en.wikipedia.org/w/index.php?title=Lokivetmab&oldid=1228745650 " C a t e g o r i e s : ● M o n o c l o n a l a n t i b o d i e s ● D o g m e d i c a t i o n s ● D e r m a t o l o g i c d r u g s t u b s H i d d e n c a t e g o r i e s : ● A r t i c l e s w i t h s h o r t d e s c r i p t i o n ● S h o r t d e s c r i p t i o n m a t c h e s W i k i d a t a ● D r u g s w i t h n o n - s t a n d a r d l e g a l s t a t u s ● A r t i c l e s w i t h o u t E B I s o u r c e ● C h e m i c a l p a g e s w i t h o u t C h e m S p i d e r I D ● C h e m i c a l p a g e s w i t h o u t D r u g B a n k i d e n t i f i e r ● A r t i c l e s w i t h o u t K E G G s o u r c e ● A r t i c l e s w i t h o u t I n C h I s o u r c e ● A r t i c l e s c o n t a i n i n g u n v e r i f i e d c h e m i c a l i n f o b o x e s ● D r u g s t h a t a r e a m o n o c l o n a l a n t i b o d y ● A l l s t u b a r t i c l e s
● T h i s p a g e w a s l a s t e d i t e d o n 1 2 J u n e 2 0 2 4 , a t 2 3 : 2 3 ( U T C ) . ● T e x t i s a v a i l a b l e u n d e r t h e C r e a t i v e C o m m o n s A t t r i b u t i o n - S h a r e A l i k e L i c e n s e 4 . 0 ;
a d d i t i o n a l t e r m s m a y a p p l y . B y u s i n g t h i s s i t e , y o u a g r e e t o t h e T e r m s o f U s e a n d P r i v a c y P o l i c y . W i k i p e d i a ® i s a r e g i s t e r e d t r a d e m a r k o f t h e W i k i m e d i a F o u n d a t i o n , I n c . , a n o n - p r o f i t o r g a n i z a t i o n . ● P r i v a c y p o l i c y ● A b o u t W i k i p e d i a ● D i s c l a i m e r s ● C o n t a c t W i k i p e d i a ● C o d e o f C o n d u c t ● D e v e l o p e r s ● S t a t i s t i c s ● C o o k i e s t a t e m e n t ● M o b i l e v i e w
